The Numbers Are In
South Korea's Ministry of Health and Welfare released its 2025 medical tourism figures on April 24, and they are striking. For the first time, foreign patients topped 2 million — 2.01 million to be exact, from 201 countries. That is a 72% jump from 2024's 1.17 million. Total spending hit roughly $8.4 billion, according to an analysis by the Korea Institute for Industrial Economics and Trade.
The growth is not slowing. Korea has now set records for three consecutive years, and the 2025 numbers nearly double the 2024 total. The ministry attributes this to post-pandemic recovery, aggressive government marketing, and Korea's entrenched reputation in cosmetic and dermatological procedures.
South Korea Medical Tourism 2025 at a Glance
- 2.01 million foreign patients (up 72% from 1.17M in 2024)
- $8.4 billion in estimated medical tourism expenditure
- 201 countries represented among visitors
- Top specialties: cosmetic surgery, dermatology, health checkups, dentistry
- Top patient sources: China, Japan, USA, Mongolia, Russia, Vietnam, Thailand
- Traditional Korean medicine revenue: record 26 billion won from foreign patients
What Drove the Surge?
Cosmetic surgery remains Korea's calling card. The country performs more procedures per capita than anywhere else on earth, and its clinics have spent decades refining everything from double-eyelid surgery to jawline contouring. But the 2025 data shows something else growing fast: health checkups and dentistry. International patients are increasingly coming not for a nose job but for a comprehensive screening package or dental implants at prices 30-50% below US rates.
Traditional Korean medicine also had a record year. Foreign spending at Korean medicine clinics hit 26 billion won in 2025, driven by interest in acupuncture, herbal medicine, and Chuna manual therapy. The government has been pushing this as a differentiated offering — something Korea has that Thailand or Singapore do not.
China's Side of the Story
China's inbound medical tourism numbers look smaller at first glance — 410,000 patients in 2025, up 38% year-on-year. But the comparison is not straightforward. China's figure counts only patients who explicitly traveled for medical purposes. Korea's 2.01 million includes anyone who received medical treatment while visiting, which captures a broader pool.
Where China is pulling ahead is in advanced therapeutics. CAR-T cell therapy, proton treatment, and complex oncology are drawing patients from Southeast Asia, the Middle East, and the former Soviet states. A CAR-T course that costs $500,000+ in the United States runs about $100,000-150,000 in China. Proton therapy wait times are 2-4 weeks versus 3-6 months in the West.
China's March 2026 hospital certification framework for international patients is also new. It creates a standardized tier system for hospitals that want to treat foreigners, covering everything from interpreter services to billing transparency. Korea has had similar infrastructure for years. China is catching up fast.
Head-to-Head Comparison
| Factor | South Korea | China |
|---|---|---|
| 2025 Inbound Patients | 2.01 million | 410,000 (medical-only count) |
| Year-on-Year Growth | 72% | 38% |
| Core Strength | Cosmetic surgery, dermatology, health checkups | CAR-T, proton therapy, advanced oncology |
| Cost vs US (index) | 30-50% of US prices | 20-40% of US prices |
| Wait Times | 1-3 weeks for most procedures | 2-4 weeks for proton; 1-2 weeks for screening |
| Traditional Medicine | Korean medicine (acupuncture, herbal, Chuna) | TCM (acupuncture, herbal, gua sha, tui na) |
| Government Support | Long-established medical tourism offices, visa facilitation | New 2026 certification framework; 9-ministry policy push |
| Language Support | English, Chinese, Russian widely available at major clinics | Improving rapidly; top-tier hospitals have full international departments |
| Best For | Cosmetic procedures, health screenings, dental work | Complex cancer treatment, cell therapy, proton treatment |
What Patients Actually Choose
The patient flow tells its own story. Korea's top source markets are China, Japan, the United States, and Mongolia — with Chinese patients making up the largest single group. That means a significant slice of Korea's 2.01 million are actually Chinese nationals who chose Seoul over Shanghai or Beijing for their procedure. The reasons vary: Korea's cosmetic surgery brand is stronger, marketing is more aggressive, and the visa process for medical travel is smoother.
China's inbound patients come from different places. Southeast Asian countries (Vietnam, Indonesia, Philippines) are growing fast. The Middle East and Central Asia are also rising. These patients are not typically coming for cosmetic work. They are coming for treatments they cannot get at home — proton therapy for pediatric cancers, CAR-T for relapsed leukemia, complex cardiac surgery.
The Bigger Picture
Both countries are growing, but they are not really competing for the same patients most of the time. Korea owns the cosmetic and wellness segment. China is building a reputation in high-acuity, technology-driven medicine. A patient flying to Seoul for a facelift and a patient flying to Shanghai for CAR-T are different people with different needs.
Where overlap exists — health checkups, dental work, some traditional medicine — price and convenience tend to decide. China's cost advantage is real. Korea's service infrastructure and international reputation are more mature. For patients in East Asia, the choice often comes down to whether they prioritize brand recognition or cost savings.
The risk for Korea is that its growth is heavily concentrated in cosmetic surgery, a market vulnerable to shifting beauty trends and regulatory crackdowns. China's risk is the opposite: its strength in advanced therapeutics depends on continued clinical success and regulatory credibility. One bad headline about a CAR-T trial or a proton center complication could slow momentum.
The Bottom Line
South Korea's 2 million patient milestone is a genuine achievement — three years of record growth and $8.4 billion in spending is hard to dismiss. But the medical tourism map is not static. China's 38% growth in advanced therapeutics, its new certification framework, and its cost advantages suggest the gap could narrow faster than Korea's headline numbers imply. For now, the two countries occupy different lanes. The question is whether either tries to cross over.
Sources: Korea Ministry of Health and Welfare (April 24, 2026), Korea Institute for Industrial Economics and Trade (April 2026), Korea JoongAng Daily (April 24, 2026), Korea.net (April 24, 2026), Asia Economic Daily (April 23, 2026), China Hospitals Guide data (April 2026).
← Back to Medical Tourism News